OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy. METHODS: A total of 210 patients were retrospectively analyzed regarding CRP values, infections, histological type, stage, performance status, gender, age, body mass index and survival. Additionally, in 88 of these patients, changes of CRP values were correlated with response to chemotherapy by radiographic imaging. RESULTS: Elevation of CRP prior to the first cycle was an adverse prognostic factor for overall survival. Comparing CRP values before and after 2 cycles correlated with response and identified patient groups with a remarkable difference of overall survival (18.8 vs. 7.5 months). Normalization of CRP was associated with a low risk for progression, whereas patients with an increase of CRP values of more than 25% showed a progressive disease in most cases. Besides performance status, no correlation of CRP with other clinical data was found. CONCLUSIONS: Measurement of CRP before initiation and during a platinum-based chemotherapy can provide prognostic information for the individual patient with advanced NSCLC and is able to support or even replace assessment of response by radiographic imaging in defined situations. Copyright 2008 S. Karger AG, Basel.
OBJECTIVE: This study was conducted to assess the prognostic role of regular measurements of C-reactive protein (CRP) in patients with advanced-stage non-small cell lung cancer (NSCLC) during platinum-based first-line therapy. METHODS: A total of 210 patients were retrospectively analyzed regarding CRP values, infections, histological type, stage, performance status, gender, age, body mass index and survival. Additionally, in 88 of these patients, changes of CRP values were correlated with response to chemotherapy by radiographic imaging. RESULTS: Elevation of CRP prior to the first cycle was an adverse prognostic factor for overall survival. Comparing CRP values before and after 2 cycles correlated with response and identified patient groups with a remarkable difference of overall survival (18.8 vs. 7.5 months). Normalization of CRP was associated with a low risk for progression, whereas patients with an increase of CRP values of more than 25% showed a progressive disease in most cases. Besides performance status, no correlation of CRP with other clinical data was found. CONCLUSIONS: Measurement of CRP before initiation and during a platinum-based chemotherapy can provide prognostic information for the individual patient with advanced NSCLC and is able to support or even replace assessment of response by radiographic imaging in defined situations. Copyright 2008 S. Karger AG, Basel.
Authors: Ondrej Fiala; Milos Pesek; Jindrich Finek; Ondrej Topolcan; Jaroslav Racek; Marek Minarik; Lucie Benesova; Zbynek Bortlicek; Alexandr Poprach; Tomas Buchler Journal: Tumour Biol Date: 2015-06-19
Authors: G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small Journal: Curr Oncol Date: 2010-08 Impact factor: 3.677
Authors: Derek Grose; Graham Devereux; Louise Brown; Richard Jones; Dave Sharma; Colin Selby; David S Morrison; Kirsty Docherty; David McIntosh; Penny McElhinney; Marianne Nicolson; Donald C McMillan; Robert Milroy Journal: Lung Cancer Int Date: 2014-03-05
Authors: Brendon J Coventry; Martin L Ashdown; Michael A Quinn; Svetomir N Markovic; Steven L Yatomi-Clarke; Andrew P Robinson Journal: J Transl Med Date: 2009-11-30 Impact factor: 5.531